Fairpointe Capital Has Lifted Its Cree (CREE) Position; 6 Analysts Covering Castlight Health, Inc. (CSLT)

December 7, 2017 - By Linda Rogers

Fairpointe Capital Llc increased Cree Inc. (CREE) stake by 8.83% reported in 2017Q2 SEC filing. Fairpointe Capital Llc acquired 492,465 shares as Cree Inc. (CREE)’s stock declined 12.84%. The Fairpointe Capital Llc holds 6.07 million shares with $149.63 million value, up from 5.58 million last quarter. Cree Inc. now has $3.38B valuation. The stock increased 1.11% or $0.38 during the last trading session, reaching $34.73. About 243,747 shares traded. Cree, Inc. (NASDAQ:CREE) has risen 2.53% since December 7, 2016 and is uptrending. It has underperformed by 14.17% the S&P500.

Among 13 analysts covering Castlight Health (NYSE:CSLT), 6 have Buy rating, 1 Sell and 6 Hold. Therefore 46% are positive. Castlight Health had 29 analyst reports since October 9, 2015 according to SRatingsIntel. FBR Capital maintained the shares of CSLT in report on Wednesday, May 11 with “Mkt Perform” rating. The firm earned “Buy” rating on Wednesday, December 16 by Topeka Capital Markets. The firm earned “Underweight” rating on Friday, May 12 by Morgan Stanley. The stock of Castlight Health, Inc. (NYSE:CSLT) earned “Underperform” rating by Morgan Stanley on Monday, May 15. The stock of Castlight Health, Inc. (NYSE:CSLT) earned “Mkt Perform” rating by FBR Capital on Wednesday, November 18. The stock has “Buy” rating by Stifel Nicolaus on Thursday, February 18. The stock of Castlight Health, Inc. (NYSE:CSLT) earned “Mkt Perform” rating by Leerink Swann on Thursday, November 5. As per Thursday, February 18, the company rating was maintained by Topeka Capital Markets. Stifel Nicolaus maintained Castlight Health, Inc. (NYSE:CSLT) rating on Thursday, November 5. Stifel Nicolaus has “Buy” rating and $7 target. The company was upgraded on Tuesday, October 10 by Canaccord Genuity. See Castlight Health, Inc. (NYSE:CSLT) latest ratings:

06/11/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $5.0 Maintain
26/10/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $5.0 Maintain
26/10/2017 Broker: Chardan Capital Markets Rating: Buy New Target: $6.3 Maintain
25/10/2017 Broker: Cantor Fitzgerald Rating: Hold New Target: $5.0
10/10/2017 Broker: Canaccord Genuity Old Rating: Hold New Rating: Buy Upgrade
06/10/2017 Broker: Canaccord Genuity Rating: Hold New Target: $5.0 Maintain
04/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $5.0 Maintain
03/08/2017 Broker: Canaccord Genuity Rating: Hold New Target: $5.0000 Maintain
10/07/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $5.0000 Maintain
30/06/2017 Broker: Canaccord Genuity Rating: Hold New Target: $5.0000 Maintain

The stock increased 4.05% or $0.15 during the last trading session, reaching $3.85. About 209,231 shares traded. Castlight Health, Inc. (NYSE:CSLT) has declined 18.00% since December 7, 2016 and is downtrending. It has underperformed by 34.70% the S&P500.

Investors sentiment increased to 1.69 in Q2 2017. Its up 0.58, from 1.11 in 2017Q1. It improved, as 16 investors sold Castlight Health, Inc. shares while 13 reduced holdings. 16 funds opened positions while 33 raised stakes. 42.32 million shares or 13.97% more from 37.14 million shares in 2017Q1 were reported. Ny State Common Retirement Fund holds 0% in Castlight Health, Inc. (NYSE:CSLT) or 49,600 shares. Prudential Public Limited Company owns 2.00 million shares. Bnp Paribas Arbitrage Sa invested in 0% or 7,033 shares. Moreover, Rhumbline Advisers has 0% invested in Castlight Health, Inc. (NYSE:CSLT) for 65,904 shares. Thompson Davis & holds 0% or 700 shares in its portfolio. 1.96M are owned by Morgan Stanley. Selz Ltd Liability Corp invested 0.89% of its portfolio in Castlight Health, Inc. (NYSE:CSLT). Royal National Bank Of Canada owns 1,511 shares for 0% of their portfolio. Needham Investment Mgmt Ltd Limited Liability Company reported 0.2% of its portfolio in Castlight Health, Inc. (NYSE:CSLT). Ameritas Invest Partners has invested 0% of its portfolio in Castlight Health, Inc. (NYSE:CSLT). Blackrock stated it has 3.40 million shares. Raymond James And accumulated 80,700 shares. Creative Planning accumulated 1,500 shares. 20,000 are held by Budros Ruhlin & Roe. General Electric holds 1.05 million shares or 2.06% of its portfolio.

Castlight Health, Inc. operates a health benefits platform in the United States. The company has market cap of $723.90 million. The companyÂ’s platform engages employees to make better health decisions and enables employers to communicate and measure their benefit programs. It currently has negative earnings. The Company’s platform also provides real-time insight into employee engagement with benefits and programs enabling employers to monitor and adjust their strategies.

Investors sentiment increased to 1.17 in 2017 Q2. Its up 0.03, from 1.14 in 2017Q1. It is positive, as 30 investors sold CREE shares while 64 reduced holdings. 27 funds opened positions while 83 raised stakes. 88.54 million shares or 6.34% more from 83.26 million shares in 2017Q1 were reported. 51 are held by First Manhattan Commerce. Ameriprise Finance Inc holds 297,889 shares or 0% of its portfolio. 18,550 are owned by Teachers Retirement Systems Of The State Of Kentucky. Oregon Public Employees Retirement Fund reported 37,170 shares or 0.02% of all its holdings. Mark Sheptoff Planning Ltd Liability invested 0% in Cree, Inc. (NASDAQ:CREE). The Florida-based State Board Of Administration Of Florida Retirement System has invested 0% in Cree, Inc. (NASDAQ:CREE). Zacks Management stated it has 0.03% in Cree, Inc. (NASDAQ:CREE). The Tennessee-based Weaver C Barksdale And Assoc Inc has invested 0.01% in Cree, Inc. (NASDAQ:CREE). The New York-based Tiaa Cref Inv Management Ltd Liability Com has invested 0% in Cree, Inc. (NASDAQ:CREE). Wells Fargo & Mn invested in 879,306 shares. Stephens Ar holds 0.04% or 48,995 shares in its portfolio. Commonwealth Equity Ser Incorporated owns 25,742 shares. 5,426 were reported by Riverhead Capital Management Limited Liability. Sei Invs Company holds 0% or 1,273 shares. Bnp Paribas Arbitrage has 0% invested in Cree, Inc. (NASDAQ:CREE).

Among 19 analysts covering Cree Inc. (NASDAQ:CREE), 5 have Buy rating, 5 Sell and 9 Hold. Therefore 26% are positive. Cree Inc. had 47 analyst reports since August 12, 2015 according to SRatingsIntel. Williams Capital Group maintained it with “Hold” rating and $24 target in Wednesday, January 25 report. The stock of Cree, Inc. (NASDAQ:CREE) earned “Hold” rating by Cowen & Co on Wednesday, August 23. TH Capital initiated the shares of CREE in report on Thursday, August 25 with “Buy” rating. Goldman Sachs maintained Cree, Inc. (NASDAQ:CREE) rating on Wednesday, October 18. Goldman Sachs has “Sell” rating and $19.0 target. Williams Capital Group downgraded the shares of CREE in report on Thursday, October 19 to “Sell” rating. The rating was downgraded by JP Morgan on Friday, October 6 to “Underweight”. The rating was downgraded by Stephens on Wednesday, August 23 to “Underweight”. The rating was maintained by Cowen & Co on Wednesday, April 6 with “Market Perform”. The firm earned “Outperform” rating on Thursday, February 4 by Northland Capital. The firm has “Neutral” rating by UBS given on Wednesday, October 19.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts